Triple-negative breast cancers (TNBCs), lacking estrogen receptor (ER), progesterone receptor, and ERBB2 (also known as HER-2/neu), are more aggressive and difficult to treat than other subtypes of breast cancers. This evidence concerns the gene ERBB2 and breast cancer.